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A B S T R A C T   
Growing evidence supports that chronic or latent infection of the central nervous system might be implicated in 
Alzheimer’s disease (AD). Among them, Herpes simplex virus type 1 (HSV-1) has emerged as a major factor in the 
etiology of the disease. Our group is devoted to the study of the relationship among HSV-1, oxidative stress (OS) 
and neurodegeneration. We have found that HSV-1 induces the main neuropathological hallmarks of AD, 
including the accumulation of intracellular amyloid beta (Aβ), hyperphosphorylated tau protein and autophagic 
vesicles, that OS exacerbates these effects, and that matrix metalloproteinase 14 (MMP-14) participates in the 
alterations induced by OS. 
In this work, we focused on the role of MMP-14 in the degenerative markers raised by HSV-1 infection. 
Interestingly, we found that MMP-14 blockage is a potent inhibitor of HSV-1 infection efficiency, that also re-
duces the degeneration markers, accumulation of Aβ and hyperphosphorylated tau, induced by the virus. Our 
results point to MMP-14 as a potent antiviral target to control HSV-1 infection and its associated neurodegen-
erative effects.   
1. Introduction 
1.1. Infectious hypothesis. Herpes simplex virus 1 in Alzheimer’s disease 
Growing evidence indicates that chronic or latent infection of the 
central nervous system might be implicated in the etiology of Alz-
heimer’s disease (AD) (see recent reviews (Fulop et al., 2018; Haas and 
Lathe 2018; Harris and Harris 2015; Itzhaki 2016)). The idea of the 
so-called infectious hypothesis came up in the 1960s and has gained 
support especially in recent years (Harris and Harris, 2015, 2018). The 
hypothesis states that in combination with genetic risk factors, these 
pathogens participate in the accumulation of the amyloid β (Aβ) peptide, 
tau hyperphosphorylation and inflammation. Numerous findings sup-
port the involvement of neurotropic viruses from the Herpesviridae 
family, especially HSV-1, in AD pathogenesis (Eimer et al., 2018; Harris 
and Harris, 2018; Itzhaki 2016, 2018). Brain autopsies showed that 
latent HSV-1 is present in a high proportion of sporadic AD and normal 
elderly individuals, and it was found in the areas most affected by AD, 
namely temporal and frontal cortices and hippocampus (Jamieson et al., 
1991). Furthermore, the viral DNA seems to colocalize with senile pla-
ques suggesting an active role of the virus in their generation (Wozniak 
et al. 2009). Evidence from epidemiological studies postulate that, in 
synergy with the possession of the APOE-ε4 allele, HSV-1 infection 
represents a risk factor for AD (Itzhaki et al., 1997). Moreover, the 
presence of IgM anti-HSV antibodies in serum-a marker of recent HSV 
reactivation-was highly correlated with the progression of the disease 
(Letenneur et al., 2008); (Lovheim et al., 2015). On the other hand, 
HSV-1 has been linked to the main neuropathological hallmarks of AD in 
cellular and animal models of HSV-1 infection: accumulation of intra-
cellular Aβ (Santana et al., 2012a, b; Wozniak et al., 2007), hyper-
phosphorylated tau protein (Alvarez et al., 2012; Wozniak et al. 2009) 
and autophagic vesicles (Itzhaki et al. 2008; Santana et al., 2012a, b). 
Our group has been studying the relationships among oxidative stress 
(OS), HSV-1 and neurodegeneration for several years. We showed that 
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OS enhances the intracellular accumulation of Aβ induced by HSV-1 
infection, and further decreased its secretion to the extracellular me-
dium. OS also potentiated the accumulation of immature autophagic 
compartments and the inhibition of the autophagic flux induced by 
HSV-1. At the same time, OS reduced the efficiency of HSV-1 infection 
(Santana et al., 2013). Moreover, functional genomic analysis of our cell 
model of infection and OS revealed the lysosome system to be impaired, 
suggesting that the interaction of OS with HSV-1 affects lysosomal 
function (Kristen et al., 2018). 
Recently, several reports have provided strong evidence of the 
implication of HSV-1 in AD pathogenesis. Multiscale analysis integrating 
genomic, transcriptomic, proteomic, and histopathological data provide 
compelling evidence that several herpesviruses (HSV-1; HHV-6A and 
HHV-7) contribute to the development of neuropathology and AD 
(Readhead et al., 2018). Moreover, Aβ binding to HSV-1 and HHV-6 
surface causes fibrillar Aβ agglutination that can protect against viral 
challenge, suggesting that Aβ can be part of the innate immune response 
to infections (Eimer et al., 2018). Finally, a big epidemiological survey 
in the Taiwanese population raised the striking observation that the risk 
of senile dementia was much greater in HSV-seropositive subjects and 
that antiviral treatment caused a dramatic decrease in the development 
of dementia (Tzeng et al., 2018). These findings have refueled the field 
leading some researchers to claim for a change in the current paradigms 
relating the causes and mechanisms of AD (Fulop et al., 2018; Haas and 
Lathe 2018). 
1.2. Role of MMPs in viral infections 
The matrix metalloproteinase family (MMPs) belongs to the met-
zincin group of proteases, which share a conserved zinc-binding motif in 
their active site. Recent data illustrate an extremely wide range of 
substrates and interconnections for these enzymes, locating them at the 
crossroads of many biological processes (Jobin et al. 2017; Young et al., 
2019). Among them, MMP-14 (also known as MT1-MMP) is highly 
expressed in brain regions that show amyloid pathology and 
neuroinflammation. 
MMPs have been shown to be involved in several viral infections. 
Excess MMP activity following infection may lead to immunopathology 
that causes host morbidity or mortality and favors pathogen dissemi-
nation or persistence (Elkington, O’Kane, and Friedland 2005). MMP-14 
contributed to Influenza-related tissue damage and mortality, and its 
selective inhibition protected the tissue from infection-related structural 
and compositional tissue damage (Talmi-Frank et al., 2016). Deficiency 
of MMP-9, a gelatinase activated by MMP-14, diminished influenza A 
infection effects in mice, lowering lung viral titers and injury, weight 
loss and mortality rates (Rojas-Quintero et al., 2018). Moreover, the 
increase of MMP-9 expression is involved in the evolution of herpes 
simplex encephalitis by facilitating the development of cerebrovascular 
complications (Martinez-Torres et al., 2004). Finally, HIV-induced 
MMP-9 activation promotes HSV-1 cell-to-cell spread in oral epithelial 
cells (Sufiawati and Tugizov 2018). Taking this relation among MMPs 
and viral infections into account, we decided to explore the role of 
MMP-14 in HSV-1 infection and the AD-like phenotype in cell models of 
neurodegeneration induced by the virus (Santana et al., 2012a, b, 2013). 
2. Materials & methods 
2.1. Cell lines 
The SK-N-MC cells derived from human neuroepithelioma (HTB-10) 
were obtained from the American Type Culture Collection. These were 
cultured as a monolayer in minimal Eagle’s medium supplemented with 
10% heat-inactivated foetal calf serum, 1 mM sodium pyruvate, non- 
essential amino acids, 2 mM glutamine, and 50 μg/mL gentamycin, at 
37 ◦C in a humidified 5% CO2 atmosphere. The murine neuroblastoma 
N2a cell line, kindly provided by P. Saftig, was cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% heat-inactivated 
foetal calf serum, 1 mM sodium pyruvate, non-essential amino acids, 
2 mM glutamine, and 50 μg/mL gentamycin, at 37 ◦C in a humidified 5% 
CO2 atmosphere. 
MMP-14 deficient cells. The knockdown of MMP-14 was performed by 
transfection of SK-N-MC cells with a short hairpin RNA (shRNA) specific 
for MMP-14 (Mission Control shRNA from Sigma, code 
TRCN0000050855) as previously described (Llorente et al., 2020); a 
scrambled shRNA (code SHC005) was used to generate the control cell 
line (named as clone 8). The clone line showing the lowest expression of 
MMP-14 was selected for further studies (named as clone 3). Culture 
conditions for these cells were the same as for the SK-N-MC parental line, 
with the selection antibiotic present throughout their growth. 
2.2. Cell treatments 
2.2.1. HSV-1 infection conditions 
The HSV-1 strain KOS 1.1 was obtained, propagated and titered on a 
monolayer of Vero cells following described methods (Carrascosa et al. 
1982) and stored at − 70 ◦C. SK-N-MC cells were seeded in complete 
media at 70–80% confluency and exposed to HSV-1 at 37 ◦C for 1 h 
(viral adsorption). In order to remove unbound virus, the medium was 
changed, and cells were incubated in complete medium at 37 ◦C. Mul-
tiplicity of infection (moi - expressed in plaque forming units per cell 
[pfu/cell]) used in all experiments was moi 1. The infected cells were 
analyzed at the hours post infection (hpi) indicated in each experiment. 
The infectious titers of HSV-1 were determined by plaque assays with 
Vero cells as previously described (Santana et al., 2012a, b). 
2.2.2. Induction of oxidative stress 
Mild oxidative stress was induced as previously described (Recuero 
et al., 2009) by adding xanthine (10 μM; Sigma) and xanthine oxidase 
(50 mU/mL; Roche) (X-XOD) for 24 h. X-XOD was added after the virus 
adsorption and maintained until the end of infection. 
2.2.3. Pharmacological inhibition of MMP-14 
MMP-14 inhibition was performed by adding the cell permeating, 
selective inhibitor NS405020 (Remacle et al., 2012), at 100 μM to the 
culture medium, unless otherwise indicated in specific experiments. 
NS405020 (APExBIO) was added after the virus adsorption and main-
tained until the end of infection, unless otherwise indicated. The effect 
of the inhibitor on cell viability was assessed by measuring the metabolic 
state of the cultures with an MTT assay as previously described (Recuero 
et al., 2009). 
Table 1 
Primary antibodies.  
Antigen Clonality Host Dilution Reference 
WB IF 
gC monoclonal mouse 1:3000 1:500 Abcam (ab6509) 
HSV-1 polyclonal rabbit – 1:500 Dako (B0114) 
ICP4 monoclonal mouse 1:1000 1:200 Abcam (ab6514) 
Aβ40 polyclonal rabbit – 1:100 Thermo Fisher 
(44344) 
Aβ42 polyclonal rabbit – 1:100 Thermo Fisher 
(44348A) 








polyclonal rabbit 1:1000 – ThermoFisher (44- 
746G) 
Tubulin monoclonal mouse 1:10000 – Sigma (T5168)  
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2.3. Cell analysis 
2.3.1. Viral DNA quantification by real-time quantitative polymerase chain 
reaction (qPCR) 
The amount of HSV-1 DNA was quantified by real-time quantitative 
PCR. DNA was extracted using the QIAamp® DNA Mini Kit (QIAGEN) 
according to the manufacturer’s instructions, as previously described 
(Santana et al., 2013). The concentration of viral DNA was then quan-
tified by qPCR with an ABI Prism 7900HT SD® system (Applied Bio-
systems) using a custom designed TaqMan probe specific for the US12 
viral gene (5′-AGGCGGCCAGAACC-3′). Viral DNA content was then 
normalized in terms of human genomic DNA, quantified with a prede-
signed TaqMan probe specific for the 18S gene (Hs99999901_s1, 
Applied Biosystems). The quantification results were represented as 
viral DNA copy numbers per ng of genomic DNA. 
2.3.2. Western blotting 
Western blotting was performed on cell extracts as previously 
described (Llorente et al., 2018) with the primary antibodies listed in 
Table 1 and horseradish peroxidase-coupled secondary antibodies. 
Immunodetection was performed using ECLTM Western Blotting 
Detection Reagents (GE Healthcare Life Sciences) according to the 
manufacturer’s instructions. To quantify the intensity of the protein 
bands, densitometric analysis was performed using Quantity One® 
Software (Bio-Rad). 
2.3.3. Immunofluorescence and immunocytochemistry 
Immunofluorescence assays were performed as previously described 
(Recuero et al., 2010), employing the primary antibodies listed in 
Table 1 and Alexa Fluor-coupled secondary antibodies. Cells were 
examined using an LSM 710 laser scanning confocal microscope (Zeiss) 
coupled to a vertical M2 AxioImager (Zeiss) equipped with a 63X/1.4 
Plan-Apochromat oil objective lens. Pictures were taken with a Spot RT 
digital camera (Diagnostic) using Zeiss ZEN 2010 imaging system soft-
ware. Images were processed using Adobe Photoshop CS3. 
Fig. 1. MMP-14 inhibition reduces HSV-1 infection. A) SK-N-MC cells were infected with HSV-1 and treated with NSC405020. Cells were compared by confocal 
microscopy adding NSC405020 24 h before, including or not the time of adsorption, or after the HSV-1 adsorption. The representative panel show immunofluo-
rescence images for anti-HSV-1 antibody and DAPI-stained nuclei. Original magnification: 63 × . Scale bar: 10 μm. Quantification of infected cells by HSV-1 staining 
was performed and the graphs show the percentage of HSV-1-positive cells. At least 200 nuclei were counted from 2 independent experiments (minimum of 100 
nuclei per experiment). Graphs depict the mean ± SEM. B & C) SK-N-MC cells were infected with HSV-1 and treated with NSC405020 after the adsorption in the 
presence or absence of X-XOD for 24 h. Western blot was performed using anti-gC, anti-ICP4 and anti α-tubulin antibodies. Numbers represent the relative ratio of the 
densitometric value normalized against α-tubulin. *p < 0.05, **p < 0.01 (n = 4 independent experiments). D) Viral DNA quantification was performed and rep-
resented as viral DNA copy numbers per ng of genomic DNA for each condition (n = 3 independent experiments). E) Cells were examined by confocal microscopy. 
The representative panel shows immunofluorescence images for anti-gC antibody and DAPI-stained nuclei. Original magnification 63 × . Scale bar 10 μm. Quan-
tification of infected cells by gC staining was performed and the graphs show the percentage of gC-positive cells. At least 450 nuclei were counted from 3 independent 
experiments (minimum of 150 nuclei per experiment). Graphs depict the mean ± SEM. 
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2.4. Statistical analysis 
Values in graphs are expressed as mean ± standard error of the mean 
(SEM). Unless otherwise indicated in specific experiments, experimental 
groups were compared paired wise and the differences were analyzed 
using the one sample t-test. Significance was set at p < 0.05. 
Fig. 2. NSC405020 inhibits HSV-1 infection of neuroblastoma cells in a dose-dependent manner. The human and murine cell lines SK-N-MC and N2a were 
infected with HSV-1 for 24 h in the absence or presence of different doses of NSC405020 added after viral adsorption. A & B) Western blot was performed using anti- 
gC and anti α-tubulin antibodies. A representative experiment is shown for the SK-N-MC (A) and N2a (B) cells. C & D) Cells were examined by fluorescence mi-
croscopy. The images show fluorescence of anti-gC antibody and DAPI-stained nuclei in SK-N-MC (C) and N2a (D) cells. Original magnification: 63 × . Scale bar: 10 
μm. E) Viral DNA quantification was performed by qPCR and represented as viral DNA copy numbers per ng of genomic DNA at the different doses of the inhibitor in 
the SK-N-MC (grey bars) and N2a (black bars) cells. Data are the mean with standard errors of two experiments. F) Cell injury induced by the inhibitor at different 
doses was measured in mock infected SK-N-MC (grey bars) and N2a (black bars) cells using the MTT reduction assay. 
Fig. 3. MMP-14 deficiency reduces HSV-1 infection. MMP-14 deficient cells (clone 3) and control cells (clone 8) were infected with HSV-1 in the presence or 
absence of X-XOD for 24 h. A) Western blot was performed using anti-MMP14 and anti α-tubulin antibodies. Numbers represent the relative ratio of the densitometric 
value normalized against α-tubulin. *p < 0.05, **p < 0.01 (n = 3 independent experiments). B & C) Western blot was performed using anti-gC, anti-ICP4 and anti 
α-tubulin antibodies. Numbers represent the relative ratio of the densitometric value normalized against α-tubulin. *p < 0.05, **p < 0.01 (n = 3 independent 
experiments). D) Cells were examined by confocal microscopy. The representative panel shows immunofluorescence images for anti-gC antibody and DAPI-stained 
nuclei. Original magnification 63 × . Scale bar 10 μm. Quantification of infected cells by gC staining was performed and the graphs show the percentage of gC- 
positive cells. At least 450 nuclei were counted from 3 independent experiments (minimum of 150 nuclei per experiment). Graphs depict the mean ± SEM. 
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3. Results 
3.1. MMP-14 inhibition or deficiency reduces HSV-1 infection 
The involvement of MMP-14 on HSV-1 infection was assessed using 
the specific inhibitor NSC405020. SK-N-MC cells were treated with the 
inhibitor for 24 h before the infection, or the inhibitor was added after 
viral adsorption. Cells were examined by immunofluorescence with an 
anti-HSV-1 antibody at 24 h post infection (hpi). As shown in Fig. 1A, 
MMP-14 inhibition produced a clear decrease in the number of infected 
cells. Interestingly, the reduction was most prominent when the inhib-
itor was added after the viral adsorption, with less than 5% of the cells 
being HSV-1 positive, compared with the 85% of HSV-1 positive cells 
without the addition of the inhibitor. When the preincubation with the 
inhibitor was maintained during the viral adsorption the number of 
HSV-1 positive cells was a 30%, whereas the preincubation with the 
inhibitor had no effect in the percentage of HSV-1 positive cells. This 
result indicated that MMP-14 is involved in HSV-1 infection and sug-
gests a role of this protein in viral post-entry steps. Taking these data 
into account, NSC405020 was added after HSV-1 adsorption in all the 
experiments. 
To quantify the effect of MMP-14 inhibition, efficiency of HSV-1 
infection was determined by assessing the levels of viral proteins and 
DNA at 24 hpi. Since it has been described by our group that OS exac-
erbates the neurodegenerative markers induced by the virus (Santana 
et al., 2013) and that OS increases the levels of MMP-14 (Llorente et al., 
2020), the infection was performed in the absence or presence of OS 
induced by the free radical-generating system X-XOD (Recuero et al., 
2009). 
Western blot analysis of SK-N-MC cell lysates were performed using 
antibodies specific for gC, that belongs to the class of γ2 ‘‘true late’’ 
genes whose expression requires viral DNA synthesis, and ICP4, an im-
mediate early protein whose expression begins before HSV-1 DNA 
replication. NSC405020 inhibitor induced a significant reduction, even 
to undetectable levels, of the gC and ICP4 amount both in the absence 
and presence of OS (Fig. 1B and C respectively). Consistent with these 
results, immunofluorescence analysis revealed that the cells treated with 
the inhibitor showed a marked decrease in the number of gC positive 
cells (approximately a 95%) (Fig. 1E), confirming the strong effect of the 
MMP-14 specific inhibitor NSC405020 on HSV-1 infection efficiency. 
Similar results were observed when the viral DNA was quantified. A 
significant decrease -higher than 95%- of viral DNA copy number in the 
presence of NSC405020 was registered (Fig. 1D). 
NSC405020 is widely reported as a repressor of tumor cell growth. 
For this reason, we next studied if the inhibition of HSV-1 infection 
could result from a decrease of cell viability. To this end, a dose curve of 
Fig. 4. MMP-14 inhibition affects early stages of 
HSV-1 infection. SK-N-MC (A–C) and N2a (D–E) 
cells were infected with HSV-1 and treated with 
NSC405020 for different times. A & B) Western blot 
was performed using anti-ICP4, anti-gC and anti 
α-tubulin antibodies. A representative experiment is 
shown. C) Cells were examined by confocal micro-
scopy at the indicated times. The representative 
panel show immunofluorescence images for anti- 
ICP4 antibody and DAPI-stained nuclei. D) West-
ern Blot and E) immunofluorescence images of N2a 
cells infected for 4 h in the absence or presence of 
NSC405020 with the anti-ICP4 antibody. Original 
magnification: 63 × . Scale bar: 10 μm.   
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the inhibitor was used, and the cell viability and infection efficiency was 
analyzed in SK-N-MC cells at 24 h post infection at the different doses. In 
addition, the murine neuroblastoma N2a cell line was used to validate 
the results in a different cell line. The results of this study are shown in 
Fig. 2. As shown in Fig. 2F, a moderate inhibition of MTT reduction was 
evidenced only at the highest concentration used (100 μM). By contrast, 
a pronounced decrease in all the indicators of the efficiency of the 
infection, including the levels of gC protein (A and B), the number of 
infected cells (C and D) and the levels of viral DNA (E), was observed 
from an inhibitor dose of 25 μM in both cell lines. According to the dose 
curves, slightly varying depending on the quantification measure used 
(viral DNA content, gC levels or percentage of infected cells), the IC50 
can be estimated between 12.5 and 25 μM for SK-N-MC cells, and around 
50 μM for N2a cells. These experiments indicated that the effect of the 
inhibitor on HSV-1 infection was much higher than that attributable to 
an inhibition of cell growth or an increase in cell mortality. 
To control for potential off-target effects of the drug, experiments in 
SK-N-MC cells stably expressing an MMP-14 specific shRNA were also 
carried out (Fig. 3). To check the efficiency of the gene silencing, MMP- 
14 levels were measured by Western blot (Fig. 3A). Viral protein levels 
and infected cell numbers were significantly lower in the MMP-14 
deficient cells (clone 3), validating the data obtained with the inhibitor. 
In sum, these results indicate that MMP-14 is involved in HSV-1 
infection of human neuroepithelioma and murine neuroblastoma cells, 
since the number of infected cells and the amount of viral DNA, gC and 
ICP4 proteins are clearly decreased when MMP-14 is inhibited. 
3.2. MMP-14 inhibition affects HSV-1 infection at early stages of the viral 
cycle 
The strong effect of MMP-14 inhibitor after the viral adsorption step 
compared with that of cell pretreatment (Fig. 1) suggested that the main 
role of this protein in the viral infectious cycle is related with intracel-
lular stages. The effect of MMP-14 on early stages of the viral cycle was 
assessed by quantifying the number of infected cells and the ICP4 levels 
by Western blot and immunofluorescence analysis. ICP4 is expressed at 
the very early stages of the infectious process, so infected cells were 
analyzed at early (2, 4, 6 hpi) and late times (24 hpi) post infection by 
Western blot (Fig. 4A). NSC405020 diminished the ICP4 levels at all 
times studied, indicating that MMP-14 plays a role in the first stages of 
infection, previous to DNA replication. As expected, the levels of gC 
were only detectable at late time (Fig. 4B), and the levels were also 
affected by the inhibitor as previously observed (Fig. 1B). 
When cells were analyzed by immunofluorescence (Fig. 4C), ICP4 
firstly showed a diffuse distribution in the nucleus, and later accumu-
lated in small, dotted structures termed pre-replicative sites. As the 
Fig. 5. MMP-14 inhibition reduces the accumulation of AD neurodegenerative markers induced by HSV-1. SK-N-MC cells were infected with HSV-1 and 
treated with NSC405020 in the presence or absence of X-XOD for 24 h and then were examined by confocal microscopy. The representative panel shows immu-
nofluorescence images for anti-Aβ40 (A), anti-Aβ42 (B), anti-tauP (thr205) (C) and anti-total tau (tau5) (D) antibodies. Original magnification 63 × . Scale bar 10 μm. 
E) SK-N-MC mock infected cells were treated with NSC405020 for 24 h and examined by fluorescence microscopy with antibodies specific for the antigens indicated 
at the top. F) Western blot was performed using anti-tauP (thr231), tau5 and anti α-tubulin antibodies. Numbers represent the relative ratio of the densitometric value 
normalized against α-tubulin and referred to the value of the mock infected, untreated cells. *p < 0.05, **p < 0.01 (n = 3 independent experiments). 
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infection progressed, large globular viral replication compartments, 
were generated, where ICP4 was involved in the transcription and 
replication of viral DNA. NSC405020 inhibitor decreased the number of 
ICP4-positive cells at all times analyzed, consistently with the results 
obtained by Western blot. These findings confirm the effect of the MMP- 
14 inhibitor in early stages of HSV-1 infection cycle. 
To validate these results, the levels of ICP4 were also measured in the 
N2a cell line. Results showed that the levels of ICP4 in Western Blot 
assays (Fig. 4D), and the number of cells stained with anti-ICP4 antibody 
(Fig. 4E) at 4 hpi were markedly reduced, indicating that the effect of 
NSC405020 in HSV-1 infection is not restricted to a unique cell line. 
3.3. MMP-14 inhibition or deficiency reduces the accumulation of AD 
neurodegenerative markers induced by HSV-1 
HSV-1 has been reported to induce neurodegenerative markers 
characteristic of AD, and these effects are exacerbated by OS (Santana 
et al., 2013). To analyze the role of MMP-14 on AD neurodegenerative 
markers induced by HSV-1, SK-N-MC cells infected with HSV-1 were 
treated with the inhibitor NSC405020, and the content of Aβ and 
phosphorylated tau were analyzed at 24 hpi in the absence or presence 
of OS (Fig. 5). 
First, Aβ levels were analyzed by immunofluorescence assays. The 
inhibitor NSC405020 caused a strong decrease of the accumulation of 
Aβ40 and Aβ42 (Fig. 5A and B respectively) in HSV-1 infected cells, both 
in the absence and presence of OS. The levels of phosphorylated tau 
were evaluated by immunofluorescence and Western blot analysis, using 
antibodies that recognize phosphorylated epitopes present in AD brains 
(thr 205 and thr 231), and the tau 5 antibody that recognizes phos-
phorylated and non-phosphorylated forms of tau. Immunofluorescence 
analysis revealed a strong decrease of phosphorylated tau staining 
(Fig. 5C) in the cells treated with NSC405020, whereas total tau seemed 
to increase in the presence of the inhibitor (Fig. 5D). Moreover, when 
phosphorylated and total tau levels were analyzed by Western blot, a 
significant decrease of phosphorylated tau (Fig. 5E) and a trend of in-
crease in total tau (Fig. 5F) was observed in the presence of the inhibitor 
NSC405020, confirming the results obtained in the immunofluorescence 
studies. 
As in the HSV-1 infection assays, AD neurodegenerative marker an-
alyses were also performed in MMP-14 silenced cells to ensure there 
were no side effects caused by the drug (Fig. 6). The accumulation of Aβ 
and phosphorylated tau decreased in MMP-14 deficient cells (clone 3) in 
Fig. 6. MMP-14 deficiency reduces the accumulation of AD neurodegenerative markers induced by HSV-1. MMP-14 deficient cells (clone 3) and control cells 
(clone 8) were infected with HSV-1 in the presence or absence of X-XOD for 24 h and then were examined by confocal microscopy. The representative panel shows 
immunofluorescence images for anti-Aβ40 (A), anti-Aβ42 (B), anti-tauP (thr205) (C) and anti-tau5 (D) antibodies. E) Mock infected cells were treated with 
NSC405020 for 24 h and examined by fluorescence microscopy with antibodies specific for the antigens indicated at the top. Original magnification 63 × . Scale bar 
10 μm. F) Western blot was performed using anti-tauP (thr231), tau5 and anti α-tubulin antibodies. Numbers represent the relative ratio of the densitometric value 
normalized against α-tubulin and referred to the value of the mock infected cells. 
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the absence or presence of OS, validating the data obtained with the 
inhibitor. Moreover, when phosphorylated and total tau levels were 
analyzed by Western blot, a relative decrease of phosphorylated tau and 
an increase in total tau (Fig. 6F) was observed in the HSV-1 infected 
deficient cells (clone 3) in comparison with the control (clone 8), what 
reinforced the results obtained in the immunofluorescence studies. 
In sum, these results indicate that the impairment of HSV-1 infection 
produced by the inhibition or deficiency of MMP-14 affects AD neuro-
degenerative events induced by the virus. 
There are previous reports showing MMP-14 as a relevant player in 
the inflammatory response raised by viral infections, and in the 
dissemination of viruses through its role as a protease degrading extra-
cellular matrix components (Jobin et al. 2017; Young et al., 2019). 
However, this is, to our knowledge, the first report showing the direct 
implication of MMP-14 in HSV-1 infectious cycle, since its inhibition 
significantly reduced the efficiency of HSV-1 infection. Further, MMP-14 
inhibition also significantly reduced the AD neurodegenerative events 
associated to HSV-1 infection, the accumulation of Aβ and phosphory-
lated tau. 
More studies are needed to reveal the mechanisms by which MMP-14 
interferes with HSV 1 infectious cycle. However, it is widely reported 
that viruses utilize endocytosis as the most common entry pathway. 
After binding to the cellular surface, the various endocytic pathways 
allow viruses to ferry their capsids through the cytoplasm where cortical 
actin filaments and other cytoplasmic barriers are overcome to reach the 
nucleus. The envelope of HSV-1 can either fuse with the plasma mem-
brane or with vesicle membranes after virions are internalized via 
endocytosis (Nicola 2016). Since MMP-14 is implicated in the lysosomal 
system, as previously described by our group (Llorente et al., 2020), the 
inhibition of MMP-14 may impair the endocytic internalization and 
dispersion of the virus within the cell. From the experiments performed 
in this work, we can conclude that MMP-14 inhibition affects early 
intracellular stages of the viral cycle of HSV-1, significantly inhibiting 
the expression of the immediate early protein ICP4. However, given the 
wide array of potential target proteins and pathways regulated by 
MMP-14 in the cell (Jobin et al. 2017), it cannot be excluded that 
additional steps of the viral cycle depending on these pathways are also 
inhibited. The use of irreversible inhibitors of the protease would be a 
valuable tool to this aim; given the renewed interest of MMP-14 as a 
pharmaceutical target (Fields 2019), these further studies are 
guaranteed. 
Our data have demonstrated that MMP-14 inhibition has a strong 
effect on HSV-1 infection and the consequent induction of neurode-
generative markers characteristic of AD brains. MMP-14 therefore has 
the potential to be a target to develop novel antiviral treatments, which 
has been previously claimed to reduce the development of dementia 
(Tzeng et al., 2018). In addition, the direct role of MMP-14 in APP 
proteolysis, recently reported by our group and others (Llorente et al., 
2020) (Paumier et al., 2019), raises the possibility that targeting 
MMP-14 could have an additional effect specifically targeting the 
upregulation of the amyloidogenic pathway induced by HSV-1. In this 
way, MMP-14 could be a good antiviral target that, in comparison with 
already known treatments, could pose additional specificity towards the 
neurodegenerative effects associated with the infection. In conclusion, 
the inhibition of MMP-14 may be particularly suitable for further 
experimental testing to develop treatment protocols for patients 
showing neurodegeneration as a consequence of HSV-1 infection, such 
as AD patients, with the aim of slowing or stopping disease progression. 
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